Form 4: Mirum Pharma Exec Granted Significant Equity Awards

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, received substantial equity awards including stock options, restricted stock units, and performance-based units.

Summary

• Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, Inc. (MIRM), was granted various equity awards on January 28, 2026.
• The awards include 7,680 stock options with an exercise price of $100.85, expiring on January 27, 2036.
• A total of 4,970 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of common stock.
• Additionally, 9,000 Performance Restricted Stock Units (PSUs) were granted, with performance criteria determined to have been met on January 28, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting routine executive compensation that aligns management incentives with shareholder interests and acknowledges past performance for PSUs. It does not, however, provide new operational or financial insights.

Positives

• The grants align the interests of a key executive, Jolanda Howe, with those of shareholders, incentivizing long-term performance.
• The vesting schedules for the stock options and RSUs encourage continued service and commitment to the company over several years.
• The vesting of PSUs indicates that certain performance criteria, established on January 23, 2024, have been successfully achieved by the company.

Risks

• The value of the equity awards is subject to the future market performance of Mirum Pharmaceuticals' common stock.
• Stock options carry the risk that the stock price may not exceed the exercise price, rendering them worthless.
• Restricted stock units and performance units are subject to forfeiture if vesting conditions (e.g., continued employment, performance targets) are not met.

Future Outlook

The equity grants indicate a long-term commitment from the executive to Mirum Pharmaceuticals, with vesting schedules extending several years into the future, contingent on continued employment and, for PSUs, previously met performance criteria. This structure aims to align executive incentives with sustained company growth and shareholder value creation.

Industry Context

StockSavvy.ai notes that executive equity compensation, such as stock options, RSUs, and PSUs, is a standard practice across the biotechnology and pharmaceutical industries. These awards are designed to attract, retain, and motivate key talent by linking their personal wealth to the company's long-term success and stock performance. The mix of time-based and performance-based awards is common, balancing retention with achievement of strategic goals.

Comparison to Industry Standards

• The use of a combination of stock options, time-vesting RSUs, and performance-vesting PSUs is a common and robust executive compensation strategy, comparable to practices at peer companies in the biotech sector such as Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN).
• The vesting schedule for stock options (1/4th after one year, then monthly over three years) and RSUs (1/3rd annually over three years) is typical for executive retention and long-term incentive plans.
• The structure of PSUs, where performance criteria are met prior to vesting, is a strong mechanism to ensure awards are earned based on tangible achievements, aligning with best practices in corporate governance for performance-based compensation.

Related Party Transactions

• Grant of 7,680 stock options to Jolanda Howe, SVP, Global Controller, on January 28, 2026.
• Grant of 4,970 Restricted Stock Units to Jolanda Howe, SVP, Global Controller, on January 28, 2026.
• Grant of 9,000 Performance Restricted Stock Units to Jolanda Howe, SVP, Global Controller, on January 28, 2026, with performance criteria met.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the interests of a key executive with shareholders, potentially leading to better long-term performance and value creation.
• Employees: This compensation structure may serve as a benchmark or incentive for other employees, demonstrating the company's commitment to performance-based rewards.

Next Steps

• Continued vesting of stock options: 1/4th of shares vest on January 28, 2027, with the balance vesting in 36 successive equal monthly installments thereafter.
• Continued vesting of Restricted Stock Units: 1/3rd of shares vest on each anniversary of January 28, 2026, until fully vested on January 28, 2029.
• Vesting of Performance Restricted Stock Units: 2/3 of shares vest on March 15, 2026, and the remaining 1/3 of shares vest on March 15, 2027.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, SEC Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, Performance Stock Units, Executive Compensation, Jolanda Howe